Drug Trial Radar · NCT03178084
Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio
Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
721
Actual
Start
Oct 15, 2014
Primary completion
Nov 5, 2016
Study completion Mar 7, 2017
Sponsor
- Lead sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of non-AIDS-related morbidity and mortality. Given the strong clinical implications the impact of different regimens on the CD4/CD8 ratio recovery needs to be analyzed. The MERIT study is a completed a randomized, double-blind, multicenter phase IIb/III study with an open-label extension phase (240-week follow-up) to assess the efficacy of zidovudine/lamivudine in combination with maraviroc (MVC) or efavirenz (EFV) in treatment-naïve patients. Anonymised patient level data of the MERIT trial to compare the trajectories of the CD4/CD8 ratio of participants treated with maraviroc vs. efavirenz will be used.
Conditions
- HIV/AIDS
Interventions
Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BIDDrug
maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
Efavirenz QD + Zidovudine/Lamivudine BIDDrug
efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QDDrug
maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in CD4/CD8 ratioTime frame: From baseline to week 120
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.